Market Valuation & Earnings Multiples
Market capitalization, P/E ratios, and enterprise value
Market Cap27.02M
Enterprise Value64.04M
HBIO
(NASDAQ)Harvard Bioscience, Inc.
$6.04-- (--)
Loading... - Market loading
Harvard Bioscience (HBIO) Key Statistics & Financial Metrics
Complete stock analysis with 40+ metrics: valuation ratios, profitability margins, financial health indicators, and dividend data.
Stock Valuation Metrics
Market value, earnings multiples, and pricing ratios
Price-Based Ratios
Valuation ratios based on stock price
Price/Sales (ttm)0.32
Forward Price/Sales0.34
Price/Book (mrq)2.69
Price/FCF (ttm)15.27
Price/OCF (ttm)8.77
Enterprise Value Ratios
EV-based valuation multiples
EV/Revenue0.75
EV/Earnings-6.55
EV/EBITDA-52.15
EV/EBIT-1.24
EV/FCF36.20
Stock Price
Current price, 52-week range, and moving averages
Current Price$6.04
1-Day Change1.34%
52-Week High$8.40
52-Week Low$0.38
52-Week Change1079.92%
YTD Change-7.35%
1-Year Change1202.85%
50-Day MA$6.15
200-Day MA$4.08
Avg Volume (30 day)24.47K
Share Statistics
Outstanding shares, float, and per-share metrics
Shares Outstanding4.47M
Book Value per Share$2.25
Net Cash per Share$-8.28
FCF per Share$0.40
Profitability & Financial Performance
Profit margins, return metrics, and earnings analysis
Profit Margins
Profitability margins across income statement
Gross Margin58.42%
EBITDA Margin (ttm)-1.44%
EBIT Margin (ttm)-60.59%
Operating Margin (ttm)1.44%
Pretax Margin (ttm)-13.25%
Profit Margin (ttm)-11.44%
FCF Margin (ttm)2.07%
Return on Investment Metrics
ROE, ROA, ROIC, and capital efficiency ratios
Return on Equity (ttm)-97.39%
Return on Assets (ttm)-12.55%
Return on Invested Capital (ttm)-86.98%
Return on Capital Employed (ttm)-95.84%
Income Statement (TTM)
Trailing twelve months revenue and earnings
Revenue85.53M
Gross Profit49.97M
Operating Income1.23M
Pretax Income-11.33M
Net Income-9.78M
EBITDA-1.23M
EBIT-51.83M
Diluted EPS$-2.20
Cash Flow (TTM)
Operating cash flow and free cash flow metrics
Operating Cash Flow3.08M
Capital Expenditures1.31M
Free Cash Flow1.77M
Growth Rates (YoY)
Year-over-year growth metrics
Revenue Growth-6.42%
Financial Health & Dividends
Balance sheet analysis, debt ratios, and dividend metrics
Assets & Cash
Total assets and cash positions
Total Assets (mrq)77.94M
Cash & Securities (mrq)7.10M
Net Cash (mrq)-37.02M
Net Cash per Share$-8.28
Debt & Liabilities
Liabilities, debt, equity, and working capital
Total Debt (mrq)44.12M
Working Capital (mrq)23.62M
Total Equity (mrq)10.05M
Book Value per Share$2.25
Liquidity & Leverage
Liquidity, leverage, and debt coverage ratios
Current Ratio (mrq)1.99
Quick Ratio (mrq)1.06
Debt/Equity (mrq)4.39
Debt/EBITDA (ttm)7.05
Debt/FCF (ttm)24.94
Dividend History & Payout Analysis
Dividend yield, payout ratios, and growth metrics
Dividend per Share (TTM)$0.00
Dividend Yield0.00%
Yield Metrics
Earnings, FCF, buyback, and shareholder yields
Earnings Yield-36.21%
FCF Yield6.55%
Buyback Yield-0.73%
Total Shareholder Yield-0.73%
Financial Health Scores
Risk assessment and quality metrics
Altman Z-Score-11.45
Piotroski F-Score4/9
Frequently Asked Questions About Harvard Bioscience Statistics
What are the key financial metrics for HBIO?
Harvard Bioscience, Inc. (HBIO) statistics include 40+ financial metrics organized into valuation ratios (P/E, P/S, P/B, PEG), profitability margins (gross, operating, net), return metrics (ROE, ROA, ROIC), and financial health indicators. These are updated regularly based on the latest filings and market data.
What is HBIO's valuation analysis?
The valuation section covers market capitalization, earnings multiples like trailing and forward P/E, price-based ratios (P/S, P/B, Price/FCF), and enterprise value ratios (EV/EBITDA, EV/Revenue, EV/FCF). Compare these against sector averages to assess whether Harvard Bioscience is overvalued or undervalued.
How do I read HBIO's profitability ratios?
Harvard Bioscience's profitability is measured through profit margins (gross, EBITDA, operating, net) and return metrics (ROE, ROA, ROIC, ROCE). Higher margins indicate better cost control, while higher returns show efficient capital deployment. The income statement and cash flow sections provide the underlying revenue and earnings data.
What do HBIO's debt ratios indicate?
The financial health section shows Harvard Bioscience's leverage through debt-to-equity, debt-to-assets, debt-to-EBITDA, and debt-to-FCF ratios, plus liquidity via the current and quick ratios. Lower debt ratios and higher liquidity ratios generally indicate stronger financial stability and lower default risk.
What is HBIO's dividend analysis?
The dividend section covers Harvard Bioscience's dividend yield, payout ratios (earnings-based and FCF-based), year-over-year dividend growth, years of consecutive growth, ex-dividend and pay dates, and payment frequency. The yield metrics section also includes earnings yield, FCF yield, buyback yield, and total shareholder yield.